» Articles » PMID: 34645707

Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis

Overview
Journal Neurology
Specialty Neurology
Date 2021 Oct 14
PMID 34645707
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Duchenne muscular dystrophy (DMD) is a rare progressive disease that is often diagnosed in early childhood and leads to considerably reduced life expectancy; because of its rarity, research literature and patient numbers are limited. To fully characterize the natural history, it is crucial to obtain appropriate estimates of the life expectancy and mortality rates of patients with DMD.

Methods: A systematic review of the published literature on mortality in DMD up to July 2020 was undertaken, specifically focusing on publications in which Kaplan-Meier (KM) survival curves with age as a timescale were presented. These were digitized, and individual patient data (IPD) were reconstructed. The pooled IPD were analyzed with the KM estimator and parametric survival analysis models. Estimates were also stratified by birth cohort.

Results: Of 1,177 articles identified, 14 publications met the inclusion criteria and provided data on 2,283 patients, of whom 1,049 had died. Median life expectancy was 22.0 years (95% confidence interval [CI] 21.2, 22.4). Analyses stratified by 3 time periods in which patients were born showed markedly increased life expectancy in more recent patient populations; patients born after 1990 have a median life expectancy of 28.1 years (95% CI 25.1, 30.3).

Discussion: This article presents a full overview of mortality across the lifetime of a patient with DMD and highlights recent improvements in survival. In the absence of large-scale prospective cohort studies or trials reporting mortality data for patients with DMD, extraction of IPD from the literature provides a viable alternative to estimating life expectancy for this patient population.

Citing Articles

Identification of suitable qPCR reference genes for the normalization of gene expression in the BL10-mdx and D2-mdx mouse models of Duchenne muscular dystrophy.

Putker K, Schneider A, van de Vijver D, Hildyard J, Aartsma-Rus A, van Putten M PLoS One. 2025; 20(2):e0318944.

PMID: 39999085 PMC: 11856590. DOI: 10.1371/journal.pone.0318944.


Real-world treatment and health care utilization among patients with Duchenne muscular dystrophy by race and ethnicity in a Medicaid population.

Posner N, Manjelievskaia J, Talaga A, Richards M, Lew C, Merla V J Manag Care Spec Pharm. 2025; 31(2):205-213.

PMID: 39912815 PMC: 11852792. DOI: 10.18553/jmcp.2025.31.2.205.


Prophylactic Use of Cardiac Medications and Survival in Duchenne Muscular Dystrophy.

Conway K, Thomas S, Neyaz T, Ciafaloni E, Mann J, Staron-Ehlinger M Muscle Nerve. 2025; 71(4):574-582.

PMID: 39853770 PMC: 11887528. DOI: 10.1002/mus.28353.


Prequalification of genome-based newborn screening for severe childhood genetic diseases through federated training based on purifying hyperselection.

Kingsmore S, Wright M, Smith L, Liang Y, Mowrey W, Protopsaltis L Am J Hum Genet. 2024; 111(12):2618-2642.

PMID: 39642867 PMC: 11639087. DOI: 10.1016/j.ajhg.2024.10.021.


Quality of life and caregiving burden associated with parenting a person with Duchenne/Becker muscular dystrophy in Poland.

Domaradzki J, Walkowiak D Orphanet J Rare Dis. 2024; 19(1):450.

PMID: 39616352 PMC: 11608484. DOI: 10.1186/s13023-024-03481-7.


References
1.
Phillips M, Quinlivan R, EDWARDS R, Calverley P . Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2001; 164(12):2191-4. DOI: 10.1164/ajrccm.164.12.2103052. View

2.
Wittlieb-Weber C, Knecht K, Villa C, Cunningham C, Conway J, Bock M . Risk Factors for Cardiac and Non-cardiac Causes of Death in Males with Duchenne Muscular Dystrophy. Pediatr Cardiol. 2020; 41(4):764-771. PMC: 7328368. DOI: 10.1007/s00246-020-02309-y. View

3.
Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y . Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med. 2013; 56(6):443-54. DOI: 10.1016/j.rehab.2013.06.002. View

4.
Hatswell A, Chandler F . Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling. Pharmacoeconomics. 2017; 35(8):755-757. DOI: 10.1007/s40273-017-0516-2. View

5.
Boland B, Silbert P, GROOVER R, Wollan P, Silverstein M . Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy. Pediatr Neurol. 1996; 14(1):7-12. DOI: 10.1016/0887-8994(95)00251-0. View